David Wien, MD
Allergy & Immunology · Wilmington, DENPI 1912904038
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 560 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.
Across 560 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$2K
- Biocryst US Sales Co., LLC$871
- CSL Behring$865
- plus $4K from 25 others
What the payments were for
- Consulting fees$1,3808%
- Speaking & faculty fees$150%
- Food & beverage$15,17490%
- Education$2411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 140 | $3,515 |
| GSK | 117 | $3,445 |
| Regeneron Healthcare Solutions, Inc. | 34 | $2,346 |
| Sanofi | 54 | $1,645 |
| Biocryst US Sales Co., LLC | 33 | $871 |
| CSL Behring | 38 | $865 |
| Genentech USA, Inc. | 15 | $546 |
| Amgen(2 entities) | 26 | $544 |
| Pharming Healthcare, Inc. | 20 | $467 |
| Optinose US, Inc. | 14 | $412 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $284 |
| Alk-abello, Inc | 7 | $278 |
| Novartis | 10 | $201 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $165 |
| Grifols USA, LLC | 2 | $148 |
| Shire North American Group Inc | 2 | $141 |
| AbbVie | 1 | $125 |
| Lilly USA, LLC | 1 | $125 |
| Sanofi-aventis U.S. LLC | 2 | $121 |
| Boehringer Ingelheim | 1 | $95 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Aimmune Therapeutics, Inc. | 4 | $66 |
| Merck | 3 | $61 |
| LEO Pharma Inc. | 3 | $58 |
| Pfizer | 3 | $57 |
| Biocryst Pharmaceuticals, Inc. | 2 | $34 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $21 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 37 | $173,293 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 162 | $141,645 |
| NucalaMepolizumab | 14 | $52,672 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $30,174 |
| Azelastine Hcl | 299 | $15,148 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,703 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $8,339 |
| Fluticasone Propionate | 270 | $4,898 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $4,672 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,252 |
| Epinephrine | 11 | $2,165 |
| Mometasone Furoate | 19 | $1,180 |
| Ipratropium Bromide | 33 | $1,067 |
| Cefdinir | 41 | $1,033 |
| Doxycycline Hyclate | 97 | $864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $3,445 | $203,020190 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,515 | $38,51451 claims |
| Hikma Pharmaceuticals USAEpinephrine | $32 | $2,16511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Wilmington
- Gregory MarcotteWilmington$17K
- Michael WydilaWilmington$7K
- Michelle SquadritoWilmington$5K
- Richard KimWilmington$4K
- Isma ShahWilmington$3K
- Trong leWilmington$220
- Junfang JiaoNewark$20K
- Sokun BhattiNewark$5K
- Lyvia LeighLewes$4K
- Muhammad KhalidNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.